🔴 Immunic is trading 5% down today amid broader risk-off sentiment

Immunic is trading 5.02% down now at $12.10, with the decline most consistent with broader risk-off sentiment.

• Its September 9, 2026 virtual R&D Day will focus on relapsing multiple sclerosis and vidofludimus calcium.
• The event is scheduled ahead of Phase 3 ENSURE topline results expected by the end of 2026.
• The S&P 500, Nasdaq Composite, and Dow Jones are down more than 0.5%; geopolitical tensions and Brent crude above $100 are pressuring equities. No company-specific negative announcement was identified.